Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis

Journal of Hypertension

Volumn 31, Issue 11, 2013, Pages 2251-2258

  Labat, Carlos ^a   Temmar, Mohamed ^b   Nagy, Edit ^c,d   Bean, Kathy ^e   Brink, Charles ^f   Benetos, Athanase ^a   Bäck, Magnus ^c,d  

^a UNIVERSITÉ DE LORRAINE   (France)

^b Telomere Cardiology Center   (Algeria)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e University Diderot   (France)

^f INSERM   (France)

Author keywords

C reactive protein; inflammation; leukotriene; pulse wave velocity; saliva

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; GELATINASE B; LEUKOTRIENE B4; LYSOZYME; PROSTAGLANDIN E2;

AGED; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHEMISTRY; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PULSE WAVE; RISK FACTOR; SALIVA; WAIST HIP RATIO;

AGED; ATHEROSCLEROSIS; BIOMARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CREATININE; DINOPROSTONE; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; LEUKOTRIENE B4; MALE; MATRIX METALLOPROTEINASE 9; METABOLIC SYNDROME X; MIDDLE AGED; MURAMIDASE; PULSE WAVE ANALYSIS; RISK FACTORS; SALIVA; VASCULAR STIFFNESS; WAIST-HIP RATIO;

EID: 84885627186     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328363dccc     Document Type: Article

References (38)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
2. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114:201-208.
3. Ketelhuth DF, BÄck M. The role of matrix metalloproteinases in atherothrombosis. Curr Atheroscler Rep 2011; 13:162-169.
4. Jonsson S, Lundberg A, Kalvegren H, Bergstrom I, Szymanowski A, Jonasson L. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris. PLoS One 2011; 6:e19340.
5. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 1992; 86:56-63.
6. Houard X, Ollivier V, Louedec L, Michel JB, BÄck M. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. FASEB J 2009; 23:1376-1383.
7. Stanke-Labesque F, Pepin JL, de Jouvencel T, Arnaud C, Baguet JP, Petri MH, et al. Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J Lipid Res 2012; 53:1944-1951.
8. BÄck M, Hlawaty H, Labat C, Michel JB, Brink C. The oral cavity and age: A site of chronic inflammation? PLoS One 2007; 2:e1351.
9. Janket SJ, Meurman JH, Nuutinen P, Qvarnstrom M, Nunn ME, Baird AE, et al. Salivary lysozyme and prevalent coronary heart disease: possible effects of oral health on endothelial dysfunction. Arterioscler Thromb Vasc Biol 2006; 26:433-434.
10. Ouellet-Morin I, Danese A, Williams B, Arseneault L. Validation of a high-sensitivity assay for C-reactive protein in human saliva. Brain Behav Immun 2011; 25:640-646.
11. Gaber F, James A, Delin I, Wetterholm A, Sampson A, Dahlén B, et al. Assessment of in vivo 5-lipoxygenase activity by analysis of leukotriene B4 in saliva: effects of treatment with zileuton. J Allergy Clin Immunol 2007; 119:1267-1268.
12. Qvarnstrom M, Janket S, Jones JA, Nuutinen P, Baird AE, Nunn ME, et al. Salivary lysozyme and prevalent hypertension. J Dent Res 2008; 87:480-484.
13. Buduneli E, Mantyla P, Emingil G, Tervahartiala T, Pussinen P, Baris N, et al. Acute myocardial infarction is reflected in salivary matrix metalloproteinase-8 activation level. J Periodontol 2011; 82:716-725.
14. BÄck M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 2009; 15:3116-3132.
15. Norel X. Prostanoid receptors in the human vascular wall. Sci World J 2007; 7:1359-1374.
16. BÄck M, Yin L, Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur Heart J 2012; 33:1928-1933.
17. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB, et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscl Thromb Vascular Biol 2009; 29:518-524.
18. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, Bean K, et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105:1202-1207.
19. Benetos A, Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoulos C, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 2004; 43:182-185.
20. Zureik M, Temmar M, Adamopoulos C, Bureau JM, Courbon D, Thomas F, et al. Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J Hypertens 2002; 20:85-93.
21. Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: A point of view from pathology. Arterioscler Thromb Vasc Biol 2010; 30:177-181.
22. Al-Shali K, House AA, Hanley AJ, Khan HM, Harris SB, Mamakeesick M, et al. Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis 2005; 178:319-325.
23. Spence JD. Carotid plaque measurement is superior to IMT. Atherosclerosis 2012; 220:34-35.
24. Mattace-Raso FU, van der Cammen TJ, van der Meer IM, Schalekamp MA, Asmar R, Hofman A, et al. C-reactive protein and arterial stiffness in older adults: the Rotterdam Study. Atherosclerosis 2004; 176:111-116.
25. Makita S, Nakamura M, Hiramori K. The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke 2005; 36:2138-2142.
26. Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001; 104:63-67.
27. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397.
28. Dillon MC, Opris DC, Kopanczyk R, Lickliter J, Cornwell HN, Bridges EG, et al. Detection of homocysteine and C-reactive protein in the saliva of healthy adults: Comparison with blood levels. Biomark Insights 2010; 5:57-61.
29. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25:372.
30. BÄck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, et al. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 2011; 63:539-584.
31. Nagy E, Andersson DC, Caidahl K, Eriksson MJ, Eriksson P, Franco-Cereceda A, et al. Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation 2011; 123:1316-1325.
32. Ingelsson E, Yin L, BÄck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol 2012; 129:702-707; e2.
33. BÄck M, Airila-Mansson S, Jogestrand T, Söder B, Söder P. Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis. Atherosclerosis 2007; 193:389-394.
34. Stanke-Labesque F, BÄck M, Lefebvre B, Tamisier R, Baguet JP, Arnol N, et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol 2009; 124:364-370; 70 e1-e2.
35. BÄck M, Sultan A, Ovchinnikova O, Hansson GK. 5- Lipoxygenaseactivating protein: A potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 2007; 100:946-949.
36. BÄck M, Bu DX, BrÄnstrom R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 2005; 102:17501-17506.
37. BÄck M, Qiu H, Haeggström JZ, Sakata K. Leukotriene B4 is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor. Am J Physiol Heart Circ Physiol 2004; 287:H419-H424.
38. Tomas I, Marinho JS, Limeres J, Santos MJ, Araujo L, Diz P. Changes in salivary composition in patients with renal failure. Arch Oral Biol 2008; 53:528-532.